ARTICLE | Company News
Nimbus Therapeutics, Gilead deal
May 23, 2016 7:00 AM UTC
Gilead completed its acquisition of the Nimbus Apollo Inc. subsidiary of Nimbus Therapeutics for $400 million up front and up to $800 million in development milestones. Nimbus Apollo will be a wholly...